Latest news with #Ingrezza
Yahoo
3 days ago
- Business
- Yahoo
Neurocrine Biosciences Grows Pipeline While Maintaining Steady Investor Confidence
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is one of the . Following the update on its ongoing clinical study, analysts are maintaining a Buy rating while raising the price target. A healthcare professional discussing treatment options for a patient with a neurological disorder. Neurocrine Biosciences, Inc. (NASDAQ:NBIX) develops therapies targeting neurological, neuroendocrine, and neuropsychiatric disorders. Operating from its headquarters in California, the company gained U.S. approval for valbenazine (Ingrezza®) for tardive dyskinesia and markets treatments for Huntington's chorea, adrenal hyperplasia, endometriosis, and uterine fibroids. The company's comprehensive pipeline includes treatments for Parkinson's, Tourette's, and novel agents like NBI‑1117568 in schizophrenia trials. Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced the termination of its Phase 2 study on NBI-921352, an investigational drug, as of July 14, 2025. The company, with its tests, aimed to evaluate the safety and tolerability of the drug when used alongside other treatments for patients with SCN8A-DEE, a rare and severe neurological disorder. Phase 2 of the study involved assessing the drug's ability to reduce seizure frequency in patients with SCN8A-DEE. As it failed to show a meaningful reduction, the study was terminated. The company's lead candidates continue to be crinecerfont for congenital adrenal hyperplasia (CAH), and NBI-1117568, a potential treatment for psychosis and cognitive disorders. Later, on July 21, 2025, Truist initiated coverage of the stock with a Buy rating and a price target of $163. On the other hand, Morgan Stanley, while maintaining the Buy rating, has raised the price target from $148 to $150. Despite the trial setback, Neurocrine Biosciences, Inc. (NASDAQ:NBIX) continues to show strong growth prospects with a 33.73% projected EPS increase and a low beta of 0.25. While we acknowledge the potential of NBIX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Metal Stocks with Insider Buying in 2025 and 10 Energy Stocks with Insider Buying in 2025 Disclosure. None. Sign in to access your portfolio
CNBC
06-05-2025
- Business
- CNBC
Stocks making the biggest moves midday: Palantir, Tesla, DoorDash, Ford and more
Check out the companies making headlines in midday trading. Palantir — Shares tumbled 13.4%. Palantir posted $884 million in first-quarter revenue , while analysts polled by LSEG penciled in $863 million. However, earnings per share came in line with Wall Street expectations at 13 cents. Ford Motor – The automaker advanced 3.2% on better-than-expected first-quarter results, reversing an earlier decline. Ford reported adjusted earnings of 14 cents per share on $37.42 billion in revenue. Analysts surveyed by LSEG expected earnings of 2 cents per share and revenue of $36.21 billion. To be sure, management suspended its 2025 guidance , citing "near-term risks, especially the potential for industrywide supply chain disruption impacting production." Upwork – Shares of the freelance marketplace platform popped 19% after the company reported a beat for both adjusted earnings and revenue for its first quarter. Upwork also lifted its full-year guidance for adjusted earnings. Tesla — The electric vehicle stock slipped 2% after data released on Tuesday showed that new car sales tumbled to a two-year low in the UK and Germany. Sales figures respectively plummeted 62% and 46% year over year for the two countries, although demand for electric vehicles still rose for both. Hims & Hers Health – Shares jumped 10.4% after the telehealth company reported a top- and bottom-line beat for the first quarter. Earnings came in at 20 cents per share, topping a consensus forecast for 12 cents per share, per LSEG. Revenue of $586 million also beat expectations for $538 million. To be sure, Hims guided for lighter-than-expected revenue in its second quarter. The telehealth provider forecast revenue to come in between $530 million to $550 million, missing the $564.6 million that analysts polled by FactSet had penciled in. DoorDash – Shares tumbled 6.8% after the food-delivery company's first-quarter revenue of $3.03 billion came below the LSEG consensus of $3.09 billion. DoorDash also announced a $1.2 billion acquisition of restaurant booking platform SevenRooms, which comes after British food delivery service Deliveroo also agreed to a takeover offer from DoorDash. Neurocrine Biosciences – The biopharmaceutical stock soared more than 9% after the company reported better-than-expected first-quarter revenue. Sales of Ingrezza, which is used to treat movement disorders, also rose 8% year over year to $545 million. Vertex Pharmaceuticals – The biotech stock plunged 13.2% on the back of weaker-than-expected quarterly results. Adjusted earnings of $4.06 per share came below the $4.32 per share LSEG estimate. Revenue came in at $2.77 billion, missing a forecast of $2.85 billion. Clorox — Shares of the cleaning products manufacturer shed 2.2% on weak fiscal third-quarter results. Clorox reported adjusted earnings of $1.45 per share on revenue of $1.67 billion during the period. Analysts polled by LSEG expected earnings of $1.57 per share on $1.73 billion in revenue. Lattice Semiconductor — The chip stock fell 12.3% after first-quarter earnings and revenue both were in line with consensus estimates. Lattice issued current-quarter forward revenue guidance between $118.5 million and $128.5 million, while analysts polled by LSEG expected $123.6 million. Adjusted earnings are estimated to range between 22 cents and 26 cents per share, versus the 24 cents per share analysts forecasted. Marriott International — The hotel and resorts company added more than 2% after posting a top- and bottom-line beat in the first quarter. Marriott reported adjusted earnings of $2.32 per share on $6.26 billion in revenue. Analysts surveyed by LSEG estimated earnings of $2.25 per share on revenues of $6.17 billion. Constellation Energy — The oil stock rallied 11.4% on better-than-expected top-line results for the first quarter. Constellation reported $6.79 billion in revenue, above the $5.44 billion expected by analysts surveyed by FactSet. — CNBC's Lisa Kailai Han, Michelle Fox, Alex Harring, Sean Conlon contributed reporting
CNBC
06-05-2025
- Business
- CNBC
Stocks making the biggest moves premarket: Palantir Technologies, Ford Motor, Vertex Pharmaceuticals, DoorDash and more
Check out the companies making headlines before the bell. Palantir Technologies – The defense technology stock fell more than 8% after it earned an adjusted 13 cents per share in the first quarter, matching analyst expectations, according to LSEG, while revenue of $884 million topped the $863 million that analysts were looking for. Palantir also boosted its full-year revenue guidance, but FactSet's StreetAccount cited a "lower magnitude of Q1 beat, weaker Europe, slowing customer growth rates, tariffs/trade tensions, and valuation" as causes of the decline. Ford Motor – The F-series pickup truck maker fell more than 2% after it suspended its 2025 guidance , citing "near-term risks, especially the potential for industrywide supply chain disruption impacting production." First-quarter earnings and auto revenue came in better than expected. Other automakers also fell premarket, with General Motors and Stellantis dropping 0.3% and almost 2%, respectively. Tesla moved down nearly 2%. Neurocrine Biosciences – Shares of the biopharmaceutical company jumped nearly 10% after its $572.6 million in revenue for the first quarter topped the $559.6 million that analysts polled by FactSet were expecting. Additionally, sales of Ingrezza, a medication used to treat movement disorders, gained 8% year over year to $545 million. Celsius Holdings – The energy drink maker's stock slid 5.6% on the back of weak first-quarter earnings. Celsius earned 15 cents per share on a GAAP basis, missing the consensus forecast of analysts polled by FactSet by 5 cents a share. Revenue came in at $329.3 million, while Wall Street had penciled in $344.2 million. Hims & Hers Health – Shares lost 6% after the company guided for lighter-than-expected revenue in its second quarter. The telehealth provider forecast revenue to come in between $530 million to $550 million, missing the $564.6 million that analysts polled by FactSet had penciled in. Hims & Hers first-quarter earnings and revenue both beat Street estimates. Vertex Pharmaceuticals – The biotech stock tumbled more than 5% on the heels of weaker-than-expected quarterly results, with adjusted earnings of $4.06 per share below the $4.25 consensus estimate, according to FactSet. Revenue came in at $2.77 billion, missing the consensus estimate of $2.86 billion. Upwork – The stock jumped 10% after the freelance marketplace platform posted first-quarter adjusted earnings of 34 cents per share on revenue of $192.7 million, beating the 27 cents a share on revenue of $188.5 million expected by analysts polled by FactSet. Upwork also raised its full-year adjusted earnings guidance to $1.14 to $1.18 per share from $1.05 to $1.10 a share, also topping analyst estimates. Clorox – The cleaning product maker slid almost 3% after posting disappointing results in its fiscal third quarter, when it earned an adjusted $1.45 per share on revenue of $1.67 billion, short of the $1.57 per share and $1.73 billion in revenue analysts were estimating, according to LSEG. Lattice Semiconductor – The chip stock slipped more than 2% after first-quarter results roughly matched expectations. Adjusted earnings per share of 22 cents were in-line with analyst estimates, according to FactSet, while revenue of $120.2 million compared to an estimate of $120.1 million. Lattice's revenue, net income and gross margin were all down year over year from the same period in 2024. DoorDash – Shares declined more than 3% after first-quarter revenue missed analyst estimates. Adjusted earnings, however, topped expectations. DoorDash also announced a $1.2 billion acquisition of restaurant booking platform SevenRooms, which comes on the heels of British food delivery service Deliveroo also agreeing to a takeover offer from DoorDash. — CNBC's Alex Harring, Jesse Pound, Lisa Kailai Han and Michelle Fox Theobald contributed reporting.
CNBC
05-05-2025
- Business
- CNBC
Stocks making the biggest moves after hours: Palantir Technologies, Ford Motor, Mattel, Clorox and more
Check out the companies making headlines in extended trading. Palantir Technologies — Shares dropped nearly 7% after the defense tech company reported first-quarter earnings that were in line with Wall Street's expectations. Adjusted earnings of 13 cents per share came in-line with the consensus estimate, per LSEG. Palantir reported $884 million in revenue, topping the $863 million forecast by analysts. Vertex Pharmaceuticals — The biotech stock dropped 2% on disappointing quarterly results. Adjusted earnings came in at $4.06 per share, below the $4.32 per share forecast by analysts surveyed by LSEG. Revenue of $2.77 billion also missed analysts' estimates for $2.85 billion. Mattel — Shares of the toymaker declined 2.5% after management paused its 2025 full-year guidance due to tariff uncertainty. Meanwhile, first-quarter results topped analysts' estimates. Neurocrine Biosciences — The maker of neurological drugs jumped 11% postmarket after first-quarter revenue of $572.6 million topped a $559.6 million estimate from analysts surveyed by FactSet. Sales of Ingrezza, used to treat movement disorders, rose 8% year-over-year to $545 million. Lattice Semiconductor — The chip stock fell 3.8% after first-quarter earnings and revenue both were in-line with consensus estimates. Lattice guided toward current quarter revenue between $118.5 million to $128.5 million, while analysts polled by LSEG expected $123.6 million. Adjusted earnings are estimated to range from 22 cents to 26 cents per share, versus the 24 cents per share analysts were looking for. Hims & Hers Health — The telehealth company dropped 1%. Guidance for second-quarter revenue came in lighter than expected, ranging from $530 million to $550 million, while analysts polled by FactSet sought $564.6 million. Earnings and revenue for the first quarter surpassed the Street's expectations, however. Ford Motor — The maker of F-series pickup trucks fell 2.7% after hours on first-quarter results showing earnings ex-items before interest and taxes (EBIT) plunged to $1.02 billion from $2.76 billion a year ago, according to FactSet. Ford estimated the net cost of higher tariffs on EBIT in 2025 at about $1.5 billion and withdrew forward guidance. Clorox – Shares of the cleaning products manufacturer fell 2.8%. Clorox posted adjusted earnings of $1.45 per share on revenue of $1.67 billion in the fiscal third quarter. That fell short of analysts' call for $1.57 per share in earnings and $1.73 billion in revenue, per LSEG. Diamondback Energy – The energy stock advanced nearly 1% after reporting better-than-expected results. Diamondback earned $4.54 per share, ex-items, in the first quarter, topping FactSet consensus estimates for $4.18 per share. Cash capital expenditures of $942 million in the period was less than the $952.8 million forecast by Wall Street. — CNBC's Darla Mercado and Scott Schnipper contributed reporting
